Loading organizations...
§ Private Profile · Redwood City, CA, USA
Clinical-stage biotechnology company developing hydroxyl dendrimer therapeutics for ophthalmology, neurology, and inflammation.
Based in Redwood City, California, Ashvattha Therapeutics is a clinical-stage biotechnology company developing targeted hydroxyl dendrimer therapeutics to treat neurological, ophthalmological, neuro-oncological, and systemic inflammatory diseases. The organization's proprietary nanomedicine platform, originally based on technology developed at Johns Hopkins University, is designed to cross biological barriers like the blood-retinal barrier to selectively reprogram activated macrophages and microglia in inflamed regions. Its clinical pipeline includes D-4517.2, a subcutaneous injection for wet age-related macular degeneration and diabetic macular edema, alongside OP-101 for severe hyperinflammation associated with COVID-19. The enterprise has secured over $100 million in total venture capital funding, which includes a $69 million Series B financing round led by Huadong Medicine with participation from Natural Capital, Plum Alley Investments, and Tribe Capital. Ashvattha Therapeutics was founded in 2015 by Jeffrey Cleland, Kannan Rangaramanujam, and Sujatha Kannan.
Ashvattha Therapeutics has raised $126.0M across 3 funding rounds.
Ashvattha Therapeutics has raised $126.0M in total across 3 funding rounds.
Ashvattha Therapeutics has raised $126.0M across 3 funding rounds. Most recently, it raised $50.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $50M Series B | Tribe Capital, JAY Zaveri | Stuart Peterson, Vasudev Bailey, BoxOne Ventures, Felicis Ventures, Original Capital, Sequel, Sequoia Capital, Social Capital, Unless, What IF Ventures, Cory Levy, Gokul Rajaram, LIU Jiang, MEI Z., Michael Stoppelman | Announced |
| Apr 1, 2022 | $69M Series B | Huadong Medicine Company Limited | Felicis Ventures, Original Capital, Sequel, Sequoia Capital, Tribe Capital, What IF Ventures, Cory Levy, Gokul Rajaram, LIU Jiang, MEI Z., Michael Stoppelman | Announced |
| Mar 1, 2019 | $7M Series A | — | Stuart Peterson, Vasudev Bailey, BoxOne Ventures, Felicis Ventures, Original Capital, Sequel, Sequoia Capital, Social Capital, Tribe Capital, Unless, What IF Ventures, Cory Levy, Gokul Rajaram, LIU Jiang, MEI Z., Michael Stoppelman | Announced |
Ashvattha Therapeutics is a clinical-stage biotechnology company developing hydroxyl dendrimer therapeutics (HDTs), a new class of nanomedicines that selectively target and reprogram activated cells in inflamed tissues.[1][2][3][4] It focuses on ophthalmology, neurology, and inflammatory diseases, with its lead candidate migaldendranib (MGB; D-4517.2) as a subcutaneous therapy for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macular edema (DME), addressing limitations of intravitreal injections by enabling at-home administration.[1][3] The company serves patients with bilateral eye diseases and neuroinflammatory conditions, solving problems of imprecise drug delivery across tissue barriers like the blood-retinal barrier, while building a pipeline of over 100 HDTs for inflammation, cancer, and autoimmune disorders; recent momentum includes January 2025 Series B extension up to $50 million and positive Phase 2 interim data showing reduced need for supplemental aflibercept injections with maintained visual acuity.[1][3]
Founded in 2015 by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland, Ashvattha emerged from novel dendrimer technology developed at Johns Hopkins University, which enables selective drug targeting to specific cell types in brain and ocular disorders.[1][2][3][5] The founders, with expertise in nanomedicine and drug delivery, incubated the company through Natural Capital to commercialize this platform via subsidiaries licensing the tech for specific indications.[2][3] Early traction built on preclinical proof-of-concept for precision targeting, evolving into clinical programs with pivotal Phase 2 data in ophthalmology by 2025.[1][3]
Ashvattha rides the nanomedicine wave in precision biotech, targeting unmet needs in back-of-the-eye diseases amid rising AMD/DME prevalence from aging populations and diabetes.[1][3] Timing aligns with advances in targeted delivery post-COVID biotech funding recovery, where subcutaneous alternatives reduce patient burden and healthcare costs versus frequent clinic visits.[1][3] Market forces like expanding wet AMD/DME markets (projected multibillion-dollar) favor its differentiators, influencing the ecosystem by pioneering dendrimer commercialization from academia and enabling subsidiary models for rapid indication expansion.[2]
Ashvattha is poised for Phase 2b/3 advancement in 2026, with topline Phase 2 presentations at key 2025 conferences signaling partnership potential with ophthalmology strategics.[3] Trends like AI-driven drug design and inflammation-focused therapies will accelerate its HDT pipeline, potentially evolving it into a multi-asset leader redefining at-home precision care. As biotech consolidates, its targeted platform could drive acquisitions, amplifying impact from eye diseases to neurology. This positions Ashvattha as a nanomedicine pioneer, transforming invasive treatments into accessible therapies.[1][3]
Ashvattha Therapeutics has raised $126.0M in total across 3 funding rounds.
Ashvattha Therapeutics's investors include Tribe Capital, Jay Zaveri, Stuart Peterson, Vasudev Bailey, BoxOne Ventures, Felicis Ventures, Original Capital, sequel, Sequoia Capital, Social Capital, Unless, What If Ventures.